Alps Advisors Inc Uni Qure N.V. Transaction History

Alps Advisors Inc

$14.5 Billion
Q2 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$16.98 - $25.54 $36,948 - $55,575	-2,176 Reduced 7.86%	25,499 $478,000
Q2 2022 Aug 11, 2022	SELL	$13.15 - $20.45 $263,894 - $410,390	-20,068 Reduced 42.03%	27,675 $516,000
Q1 2022 May 16, 2022	SELL	$14.54 - $21.5 $83,270 - $123,130	-5,727 Reduced 10.71%	47,743 $863,000
Q4 2021 Feb 09, 2022	BUY	$20.24 - $36.01 $1.08 Million - $1.93 Million	53,470 New	53,470 $1.11 Million
Q2 2021 Aug 11, 2021	SELL	$29.97 - $37.17 $2.44 Million - $3.03 Million	-81,401 Closed	0 $0
Q1 2021 May 07, 2021	BUY	$29.24 - $42.03 $31,111 - $44,719	1,064 Added 1.32%	81,401 $2.74 Million
Q4 2020 Feb 03, 2021	BUY	$35.35 - $50.67 $836,274 - $1.2 Million	23,657 Added 41.74%	80,337 $2.9 Million
Q3 2020 Nov 04, 2020	SELL	$35.98 - $47.66 $58,539 - $77,542	-1,627 Reduced 2.79%	56,680 $2.09 Million
Q2 2020 Aug 05, 2020	SELL	$45.06 - $67.74 $874,389 - $1.31 Million	-19,405 Reduced 24.97%	58,307 $2.63 Million
Q1 2020 May 06, 2020	SELL	$40.01 - $73.97 $334,283 - $618,019	-8,355 Reduced 9.71%	77,712 $3.69 Million
Q4 2019 Feb 07, 2020	BUY	$37.13 - $74.62 $33,008 - $66,337	889 Added 1.04%	86,067 $6.17 Million
Q3 2019 Nov 04, 2019	BUY	$39.36 - $76.8 $263,830 - $514,790	6,703 Added 8.54%	85,178 $3.35 Million
Q2 2019 Aug 07, 2019	SELL	$52.76 - $82.19 $567,117 - $883,460	-10,749 Reduced 12.05%	78,475 $6.13 Million
Q1 2019 May 01, 2019	BUY	$27.39 - $68.41 $105,725 - $264,062	3,860 Added 4.52%	89,224 $5.32 Million
Q4 2018 Feb 04, 2019	BUY	$22.8 - $33.93 $1.95 Million - $2.9 Million	85,364 New	85,364 $2.46 Million

Others Institutions Holding QURE

# of Institutions

142

Shares Held

35.3M

Call Options Held

1.54M

Put Options Held

389K

View Full List

About uniQure N.V.

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

More about QURE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.

Account